Hanmi Pharmaceutical, based in Korea, has announced a Clinical Trial Collaboration and Supply Agreement with the global healthcare company Merck & Co., Inc. The agreement stipulates that Hanmi Pharmaceutical will commence a phase 1 clinical trial which will assess the safety and effectiveness of their immuno-oncology drug, 'BH3120'. The trial will test the drug in conjunction with Merck's anti-PD-1 therapy, Keytruda, in patients who exhibit progressive or metastatic solid tumors. Hanmi Pharmaceutical will act as the trial’s sponsor, and Merck will provide Keytruda.
The immuno-oncology drug 'BH3120' incorporates 'Pentambody', a cutting-edge bispecific antibody platform technology. It is currently in the process of joint development between Hanmi Pharmaceutical and their Chinese offshoot, Beijing Hanmi Pharmaceutical. For further updates in the health sector, please visit rttnews.com.
